Helen Ryan, MD
Hematology & Oncology · Kennebunk, MENPI 1477575793
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Bristol Myers Squibb at 27.6% of the total. Reporting peaked in 2019 at $47,819 and has fallen 99.4% since, to $268 in 2025. Among hematology & oncology clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 101 payments — averaging $821.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$23K
- Kyowa Kirin, Inc.$9K
- Seagen Inc.$8K
- AstraZeneca$4K
- Jazz Pharmaceuticals Inc.$4K
- Genentech USA, Inc.$4K
- plus $30K from 21 others
Across 43 payments — averaging $326.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pharmacyclics LLC, An Abbvie Company$8K
- Amgen$6K
- Janssen Research & Development, LLC$465
What the payments were for
- Consulting fees$38,56646%
- Speaking & faculty fees$33,11940%
- Travel & lodging$8,62210%
- Food & beverage$2,5033%
- Education$1980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 22 | $22,930 |
| Kyowa Kirin, Inc. | 10 | $9,302 |
| Seagen Inc. | 8 | $8,276 |
| AstraZeneca | 9 | $4,439 |
| Jazz Pharmaceuticals Inc. | 6 | $4,328 |
| Genentech USA, Inc. | 4 | $3,815 |
| Amgen | 3 | $3,796 |
| Gilead | 7 | $3,614 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $3,432 |
| Partner Therapeutics, Inc. | 4 | $3,128 |
| Agios Pharmaceuticals, Inc. | 1 | $2,400 |
| GSK | 2 | $2,350 |
| Incyte Corporation | 2 | $2,284 |
| Blueprint Medicines Corporation | 1 | $1,640 |
| Karyopharm Therapeutics Inc. | 1 | $1,550 |
| Pfizer | 1 | $1,500 |
| Beigene USA, Inc. | 1 | $1,350 |
| Verastem, Inc. | 1 | $1,320 |
| Johnson & Johnson | 1 | $988 |
| Syndax Pharmaceuticals, Inc. | 1 | $129 |
| E.r. Squibb & Sons, L.L.C. | 1 | $120 |
| Exelixis Inc. | 1 | $110 |
| Genentech, Inc. | 2 | $94 |
| Rigel Pharmaceuticals, Inc. | 2 | $41 |
| Novartis | 2 | $33 |
| AbbVie | 1 | $29 |
| Astellas Pharma US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$83,007 in reported general payments places this provider in the 95th percentile of 60 hematology & oncology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Kennebunk
- Can IlyasKennebunk$1K
- Kurt EbrahimKennebunk$129
- Matthew DuganWestbrook$577K
- John WintersWestbrook$341K
- Eleni NackosWestbrook$79K
- Christian ThomasWestbrook$54K
- Devon EvansWestbrook$31K
- Tracey WeisbergWestbrook$31K
- Daniel RauschWestbrook$20K
- Patrick BolandWestbrook$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.